Gastrointestinal and eating problems in SCN1A-related seizure disorders.


Journal

Epilepsy & behavior : E&B
ISSN: 1525-5069
Titre abrégé: Epilepsy Behav
Pays: United States
ID NLM: 100892858

Informations de publication

Date de publication:
09 2023
Historique:
received: 25 05 2023
revised: 13 07 2023
accepted: 13 07 2023
medline: 11 9 2023
pubmed: 31 7 2023
entrez: 31 7 2023
Statut: ppublish

Résumé

Our study aimed to describe the prevalence and characteristics of gastrointestinal and eating problems in Dravet syndrome (DS) and other SCN1A-related seizure disorders and to determine the association between the occurrence of gastrointestinal and eating problems and core features of DS. Gastrointestinal and eating problems were assessed with a questionnaire in a Dutch cohort of participants with an SCN1A-related seizure disorder. Associations between the number of gastrointestinal and eating problems and core features of DS, seizure severity, level of intellectual disability, impaired mobility, behavioral problems, and use of anti-seizure medication, were explored by multivariate ordinal regression analyses. Symptoms were divided into the categories dysphagia-related, behavioral, and gastrointestinal, and were assessed separately. One hundred sixty-nine participants with an SCN1A-related seizure disorder, of whom 118 (69.8%) with DS and 51 (30.2%) with Generalized Epilepsy with Febrile Seizures Plus / Febrile Seizures (GEFS+/FS), the non-DS phenotype, were evaluated. Gastrointestinal and eating problems were highly prevalent in DS participants, 50.8% had more than three symptoms compared to 3.9% of non-DS participants. Of participants with DS, 17.8% were fully or partly fed by a gastric tube. Within the three different symptom categories, the most prevalent dysphagia-related symptom was drooling (60.7%), distraction during mealtimes (61.4%) the most prevalent behavioral symptom, and constipation and loss of appetite (both 50.4%) the most prevalent gastrointestinal symptoms. DS participants who use a wheelchair (odds ratio (OR) 4.9 95%CI (1.9-12.8) compared to walking without aid), who use ≥3 anti-seizure medications (ASM) (OR 5.9 95%CI (1.9-18.2) compared to <3 ASM) and who have behavioral problems (OR 3.0 95%CI (1.1-8.1) compared to no behavioral problems) had more gastrointestinal and eating problems. Gastrointestinal and eating problems are frequently reported symptoms in DS. Distinguishing between symptom categories will lead to tailored management of patients at risk, will improve early detection, and enable a timely referral to a dietitian, behavioral expert, and/or speech therapist, ultimately aiming to improve the quality of life of both patients and caregivers.

Identifiants

pubmed: 37523795
pii: S1525-5050(23)00280-9
doi: 10.1016/j.yebeh.2023.109361
pii:
doi:

Substances chimiques

NAV1.1 Voltage-Gated Sodium Channel 0
SCN1A protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109361

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

C A Minderhoud (CA)

Department of Neurology, UMCU Brain Center, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, the Netherlands. Electronic address: c.a.minderhoud-2@umcutrecht.nl.

A Postma (A)

Department of Psychiatry, UMCU Brain Center, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, the Netherlands.

F E Jansen (FE)

Department of Neurology, UMCU Brain Center, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, the Netherlands.

J S Verhoeven (JS)

Department of Neurology, Academic Centre for Epileptology Kempenhaeghe, Heeze, the Netherlands.

J J Schrijver (JJ)

Department of Dietetics, University Medical Center Utrecht, Utrecht, the Netherlands.

J Goudswaard (J)

Speech Therapy, Stichting Epilepsie Instellingen Nederland, Postbus 540, 2130 AM Hoofddorp, the Netherlands.

G Andreae (G)

Speech Therapy, Stichting Epilepsie Instellingen Nederland, Postbus 540, 2130 AM Hoofddorp, the Netherlands.

W M Otte (WM)

Department of Neurology, UMCU Brain Center, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, the Netherlands.

K P J Braun (KPJ)

Department of Neurology, UMCU Brain Center, University Medical Center Utrecht, Heidelberglaan 100, 3584CX Utrecht, the Netherlands.

E H Brilstra (EH)

Department of Genetics, UMC Utrecht Brain Center, University Medical Center Utrecht, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH